Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark.
| Title: | Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark. |
|---|---|
| Authors: | Dalvi T; AstraZeneca, One MedImmune Way, Gaithersburg, Maryland, United States of America.; Nørgaard M; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus N, Denmark.; Fryzek JP; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus N, Denmark.; EpidStrategies, Rockville, Maryland, United States of America.; Movva N; EpidStrategies, Rockville, Maryland, United States of America.; Pedersen L; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus N, Denmark.; Pham Hansen H; Institute of Pathology, Aarhus University Hospital, Aarhus N, Denmark.; Walker J; AstraZeneca, Cambridge, United Kingdom.; Midha A; AstraZeneca, Cambridge, United Kingdom.; Shire N; AstraZeneca, One MedImmune Way, Gaithersburg, Maryland, United States of America.; Boothman AM; AstraZeneca, Cambridge, United Kingdom.; Rigas J; AstraZeneca, One MedImmune Way, Gaithersburg, Maryland, United States of America.; Mellemgaard A; AstraZeneca, Cambridge, United Kingdom.; Department of Oncology, Bornholm Hospital, Rønne, Denmark.; Rasmussen TR; Dansk Lunge Cancer Gruppe, Odense, Denmark.; Department of Respiratory Medicine, Aarhus University Hospital, Aarhus N, Denmark.; Hamilton-Dutoit S; Institute of Pathology, Aarhus University Hospital, Aarhus N, Denmark.; Cronin-Fenton D; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus N, Denmark. |
| Source: | PloS one [PLoS One] 2023 Apr 11; Vol. 18 (4), pp. e0284037. Date of Electronic Publication: 2023 Apr 11 (Print Publication: 2023). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: San Francisco, CA : Public Library of Science |
| MeSH Terms: | Carcinoma, Non-Small-Cell Lung*/pathology ; Lung Neoplasms*/pathology; B7-H1 Antigen/metabolism ; Proto-Oncogene Proteins p21(ras)/metabolism ; ErbB Receptors/metabolism ; Humans ; Biomarkers, Tumor ; Denmark |
| Abstract: | Introduction: Programmed cell death ligand-1 (PD-L1) expression may help identify patients with non-small cell lung cancer (NSCLC) who would benefit from immunotherapy. We assessed PD-L1 expression, and epidermal growth factor receptor (EGFR) and V-Ki-Ras2 Kirsten rat sarcoma (KRAS) mutations in NSCLC patients receiving adjuvant chemotherapy.; Methods: Data for stage IB/II/IIIA NSCLC patients (diagnosed: 2001-2012) were retrieved from Danish population-based registries. Tumor tissue samples were tested for PD-L1 expression using VENTANA PD-L1 (SP263) Assay in tumor cells (TC) at ≥25% cutoff and immune cells (IC) at ≥1% and ≥25% cutoffs. KRAS and EGFR mutations were tested using PCR-based assays. Follow-up began 120 days after diagnosis until death/emigration/January 1, 2015, whichever came first. Using Cox proportional hazard regression, hazard ratios (HRs) were computed for overall survival (OS) for each biomarker, adjusting for age, sex, histology, comorbidities, and tissue specimen age.; Results: Among 391 patients identified, 40.4% had stage IIIA disease, 49.9% stage II, and 8.7% stage IB. PD-L1-TC was observed in 38% of patients, EGFR mutations in 4%, and KRAS mutations in 29%. KRAS mutations were more frequent among patients with PD-L1 TC≥25% versus TC |
| Competing Interests: | Tapashi Dalvi, Jill Walker, Anita Midha, Norah Shire, Anders Mellemgaard, and Anne Marie Boothman are employees of AstraZeneca. Tapashi Dalvi, Jill Walker, Anita Midha, and Anne Marie Boothman own stock in AstraZeneca. Jon P. Fryzek and Naimisha Movva are employees of EpidStrategies. James Rigas was an employee of AstraZeneca during the study period. This does not alter our adherence to PLOS ONE policies on sharing data and materials. However, Danish law does not allow researchers to share raw data from the registries with third parties. Data can be accessed by researchers through application to the Danish Data Protection Agency and the Danish Health Data Authority. This does not alter our adherence to PLOS ONE policies on sharing data and materials. |
| References: | J Thorac Oncol. 2016 Jul;11(7):1003-11. (PMID: 27103510); Lung Cancer. 2017 Oct;112:200-215. (PMID: 29191596); J Thorac Oncol. 2017 Feb;12(2):208-222. (PMID: 27913228); J Clin Oncol. 2013 Jun 10;31(17):2173-81. (PMID: 23630215); Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21. (PMID: 28881918); J Clin Oncol. 2005 May 10;23(14):3270-8. (PMID: 15886314); Scand J Soc Med. 1998 Dec;26(4):293-8. (PMID: 9868755); Nature. 2018 Jan 24;553(7689):446-454. (PMID: 29364287); Thorac Cancer. 2015 Jul;6(4):534-8. (PMID: 26273411); Lung Cancer. 2019 Aug;134:174-179. (PMID: 31319978); Transl Oncol. 2016 Feb;9(1):64-69. (PMID: 26947883); Eur J Cancer. 2014 May;50(7):1361-9. (PMID: 24548766); N Engl J Med. 2018 May 31;378(22):2078-2092. (PMID: 29658856); Br J Cancer. 2013 Sep 3;109(5):1264-70. (PMID: 23942067); Oncotarget. 2016 Feb 16;7(7):8373-88. (PMID: 26840022); Science. 2000 Mar 31;287(5462):2398-9. (PMID: 10766613); Lung Cancer. 2015 Aug;89(2):181-8. (PMID: 26024796); Cancer Immunol Immunother. 2007 Aug;56(8):1173-82. (PMID: 17186290); Br J Cancer. 2011 Jun 28;105(1):93-103. (PMID: 21629244); Dan Med Bull. 1999 Jun;46(3):263-8. (PMID: 10421985); Dan Med Bull. 1997 Nov;44(5):535-9. (PMID: 9408738); Oncotarget. 2017 Jun 27;8(37):61618-61625. (PMID: 28977890); Clin Cancer Res. 2015 Sep 1;21(17):4014-21. (PMID: 26019170); Clin Epidemiol. 2010 Aug 09;2:51-6. (PMID: 20865103); Clin Cancer Res. 2007 Apr 1;13(7):2151-7. (PMID: 17404099); Lung Cancer. 2018 Oct;124:310-316. (PMID: 30119925); Lancet Oncol. 2011 Feb;12(2):175-80. (PMID: 21277552); Scand J Public Health. 2011 Jul;39(7 Suppl):42-5. (PMID: 21775350); Onco Targets Ther. 2014 Apr 12;7:567-73. (PMID: 24748806); Clin Epidemiol. 2016 Oct 25;8:537-541. (PMID: 27822096); Expert Opin Drug Metab Toxicol. 2020 Feb;16(2):87-96. (PMID: 31978315); J Clin Transl Res. 2021 Jan 20;7(1):1-21. (PMID: 34104805); N Engl J Med. 2018 Dec 13;379(24):2342-2350. (PMID: 30280658); J Thorac Oncol. 2009 Jan;4(1):1-4. (PMID: 19096299); Br J Cancer. 2015 Jan 6;112(1):95-102. (PMID: 25349974); Clin Epidemiol. 2015 Nov 17;7:449-90. (PMID: 26604824); Eur J Epidemiol. 2014 Aug;29(8):541-9. (PMID: 24965263); Diagn Pathol. 2016 Oct 8;11(1):95. (PMID: 27717372); J Thorac Oncol. 2018 Sep;13(9):1302-1311. (PMID: 29800747); Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5. (PMID: 17360651); Cancer. 2010 Apr 1;116(7):1757-66. (PMID: 20143437); Lancet Oncol. 2014 Jan;15(1):23-34. (PMID: 24314615); PLoS One. 2011;6(9):e23621. (PMID: 21912640); CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593); Transl Lung Cancer Res. 2014 Aug;3(4):242-9. (PMID: 25806307) |
| Substance Nomenclature: | 0 (B7-H1 Antigen); EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)); 0 (Biomarkers, Tumor); EC 2.7.10.1 (ErbB Receptors) |
| Entry Date(s): | Date Created: 20230411 Date Completed: 20230413 Latest Revision: 20230418 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10089313 |
| DOI: | 10.1371/journal.pone.0284037 |
| PMID: | 37040387 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't